TNYA — Tenaya Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1858848 ·
Last close
$0.87
Market Cap
$188.88M
52W High
$1.15
52W Low
$0.65
ADV30
3,136,553
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 225,000 | — | -20,065,000 | -19,272,000 | 135,070,000 | 80,887,000 | 28,881,000 |
| Dec 2025 | 0 | — | -20,775,000 | -20,175,000 | 146,921,000 | 100,547,000 | 23,656,000 |
| Sep 2025 | 0 | — | -20,936,000 | -20,275,000 | 104,980,000 | 56,312,000 | 22,112,000 |
| Jun 2025 | 0 | — | -24,082,000 | -23,283,000 | 122,151,000 | 62,671,000 | 22,323,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-68,264,000
Investing CF
$56,083,000
Financing CF
$108,405,000
CapEx
$-618,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.62
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-605,008,000
Inventory
—
Receivables
—
ST Investments
$0
EBIT TTM
$-93,331,000
Pretax Income TTM
$-90,597,000
Interest Exp TTM
—
Analysts
5
Yahoo Snapshot (yfinance, live)
Total Revenue
$225,000
EBITDA
$-78,320,000
Free Cash Flow
$-41,898,248
Enterprise Value
$113,679,048
Total Cash
$80,887,000
Total Debt
$10,117,000
Shares Out
216,998,876
Trailing EPS
$-0.44
Book Value
$0.49
ROE
-73.6%
ROA
-38.5%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -93,331,000 | -90,597,000 | 146,921,000 | 23,656,000 | — | -68,264,000 |
| Dec 2024 | 0 | -115,948,000 | -111,129,000 | 119,940,000 | 27,086,000 | — | -90,501,000 |
| Dec 2023 | 0 | -131,193,000 | -124,084,000 | 170,515,000 | 31,091,000 | — | -102,072,000 |
| Dec 2022 | 0 | -125,621,000 | -123,665,000 | 278,945,000 | 35,569,000 | — | -104,424,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.41
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| OTLK | Outlook Therapeutics, Inc. | $189.76M | $1.57 | — |
| ABOS | Acumen Pharmaceuticals, Inc. | $189.96M | $2.63 | — |
| HUMA | Humacyte, Inc. | $187.05M | $0.69 | — |
| CRBU | Caribou Biosciences, Inc. | $190.92M | $1.92 | — |
| ACOG | Alpha Cognition Inc. | $183.12M | $8.41 | — |
News headlines (Yahoo Finance, 1h cache)
Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer
2026-06-29 12:30 · Yahoo
Exploring 3 High Growth Tech Stocks in US Market
2026-06-15 11:39 · Yahoo
Exploring High Growth Tech Stocks In The US Market
2026-06-11 11:38 · Yahoo
Exploring 3 High Growth Tech Stocks In The US Market
2026-06-05 17:38 · Yahoo
US High Growth Tech Stocks with Promising Potential
2026-06-05 11:38 · Yahoo
High Growth Tech Stocks To Watch In US June 2026
2026-06-03 11:38 · Yahoo
Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Sympt
2026-06-03 11:00 · Yahoo
Tenaya Therapeutics to Announce New Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026
2026-06-02 20:30 · Yahoo
Top 3 High Growth Tech Stocks in the US Market
2026-06-01 17:38 · Yahoo
High Growth Tech Stocks in US for May 2026
2026-05-29 17:38 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.